Clinical Trial Update: Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2b trial evaluating Velcade (bortezomib) alone and in combination with irinotecan for relapsed or refractory colorectal carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Carcinoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Colorectal Carcinoma | Phase 2 | Status: COMPLETED